<DOC>
	<DOCNO>NCT00950794</DOCNO>
	<brief_summary>To demonstrate efficacy ( non-inferiority ) Salmeterol 50mcg bid ( 100mcg/day ) , compare Hokunalin ( tulobuterol ) tape 2mg day , term improvement pulmonary function ( peak expiratory flow : PEF ) randomize , double-blind , parallel-group comparative study adult patient bronchial asthma ICS 400mcg/day FP equivalent .</brief_summary>
	<brief_title>Study Salmeterol ( SN408D ) Adult Asthma</brief_title>
	<detailed_description>Primary To demonstrate efficacy ( non-inferiority ) Salmeterol 50mcg bid ( 100mcg/day ) , compare Hokunalin ( tulobuterol ) tape 2mg day , term improvement pulmonary function ( peak expiratory flow : PEF ) randomize , double-blind , parallel-group comparative study adult patient bronchial asthma ICS 400mcg/day FP equivalent . Secondary - To evaluate efficacy Salmeterol , compare Hokunalin ( tulobuterol ) tape term asthma symptom record asthma diary . - To evaluate safety Serevent compare Hokunalin ( tulobuterol ) tape .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Tulobuterol</mesh_term>
	<mesh_term>Terbutaline</mesh_term>
	<criteria>For entry runin period ( Visit 1 ) A subject consider eligible inclusion study follow criterion apply : 1 . Males female age &gt; = 15 year time give informed consent . 2 . Subjects able give write informed consent participation study . However , subject age &lt; 20 year time give informed consent , write informed consent obtain subject his/her legally acceptable representative . 3 . Outpatients . 4 . Subjects diagnose asthma least 6 month prior Visit 1 . 5 . Subjects receive ICS 400mcg/day FP equivalent least 8 week prior Visit 1 . For entry treatment period ( Visit 2 ) A subject consider eligible enter treatment period he/she complete runin period meet follow criterion : 1 . Subjects meet follow criterion term pulmonary function . Has mean morning PEF last 7 day ( least 4 day ) prior Visit 2 &gt; = 40 % predict value . Has least 2 day diurnal variation PEF &gt; = 15 % runin period , confirm record reversibility &gt; = 15 % use rapidacting inhaled beta2 agonist within 3 month prior Visit 1 ( include Visit 1 ) . 2 . Subjects &gt; = 70 % compliance asthma medication runin period . 3 . Subjects able measure peak flow correctly runin period , investigator's/subinvestigator 's judgment . 4 . Subjects able keep asthma diary correctly runin period , investigator's/subinvestigator 's judgment . A subject eligible inclusion study follow criterion apply Visit 1 Visit 2 : 1 . Subjects receive injected steroid , inject ACTH , oral steroid within four week Visit1 runin period . 2 . Subjects receive xanthine ( oral , injected , suppository ) , beta2 agonist rescue medication ( rapidacting inhale beta2 agonist ) , inhaled anticholinergic runin period . 3 . Subjects respiratory disease asthma ( e.g. , chronic bronchitis , emphysema , bronchiectasis , pulmonary fibrosis , lung cancer , sarcoidosis , old tuberculosis ) , judgment investigator/subinvestigator , likely affect efficacy evaluation . 4 . Subjects uncontrollable diabetes mellitus , hypertension , heart disease , hyperthyroidism , inappropriate study judgement investigator/sub investigator . 5 . Subjects unsuitable study judgment investigator/subinvestigator base 12lead ECG finding Visit 1 . 6 . Subjects regularly use medication contain follow ingredient : betablockers , alpha/betablockers 7 . Subjects receive immunosuppressive medication exclude Tacrolimus ointment . 8 . Subjects receive catecholamine . 9 . Subjects atopic dermatitis inappropriate study judgment investigator/subinvestigator . 10 . Subjects suspect hypersensitivity investigational product . 11 . Subjects receive last dose investigational drug past 30 day . 12 . Subject currently pregnant , possibly pregnant , lactate willing become pregnant study period . 13 . Subjects consume alcohol drug excessively opinion investigator/subinvestigator . 14 . Subjects judge investigator/subinvestigator Step 4 asthma ( severe persistent ) , refer `` GINA2002 '' `` JGL2003 '' ï¼Ž 15 . Subjects judge investigator/subinvestigator inappropriate study reason .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Long act beta2-agonist</keyword>
</DOC>